These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 29980849

  • 1. Protocol biopsies in pediatric renal transplantation: a precious tool for clinical management.
    Zotta F, Guzzo I, Morolli F, Diomedi-Camassei F, Dello Strologo L.
    Pediatr Nephrol; 2018 Nov; 33(11):2167-2175. PubMed ID: 29980849
    [Abstract] [Full Text] [Related]

  • 2. Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients.
    Sethi S, Najjar R, Peng A, Choi J, Lim K, Vo A, Jordan SC, Huang E.
    Transplantation; 2020 Jul; 104(7):1500-1507. PubMed ID: 31568398
    [Abstract] [Full Text] [Related]

  • 3. Utility of Serial Protocol Biopsies Performed After 1 Year in Predicting Long-Term Kidney Allograft Function According to Histologic Phenotype.
    Zachariah MS, Dwivedi AK, Yip CS, Chang SS, Gundroo A, Venuto RC, Tomaszewski J, Patel SK, Sharma R.
    Exp Clin Transplant; 2018 Aug; 16(4):391-400. PubMed ID: 29206090
    [Abstract] [Full Text] [Related]

  • 4. Renin-Angiotensin System Blockage and Avoiding High Doses of Calcineurin Inhibitors Prevent Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.
    Sayin B, Canver B, Gurlek Demirci B, Colak T, Ozdemir BH, Haberal M.
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):32-36. PubMed ID: 28260428
    [Abstract] [Full Text] [Related]

  • 5. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A, Felipe C, Cristelli M, Viana L, Basso G, Stopa S, Mansur J, Ivani M, Bessa A, Ruppel P, Aguiar W, Campos E, Gerbase-DeLima M, Proença H, Tedesco-Silva H, Medina-Pestana J.
    Am J Nephrol; 2017 Feb; 45(6):497-508. PubMed ID: 28511172
    [Abstract] [Full Text] [Related]

  • 6. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
    Rivelli RF, Gonçalves RT, Leite M, Santos MA, Delgado AG, Cardoso LR, Takiya CM.
    Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
    [Abstract] [Full Text] [Related]

  • 7. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
    de Sandes-Freitas TV, Felipe CR, Campos ÉF, de Lima MG, Soares MF, de Franco MF, Aguiar WF, Tedesco-Silva H, Medina-Pestana JO.
    Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
    [Abstract] [Full Text] [Related]

  • 8. Protocol biopsies in pediatric renal transplant recipients on cyclosporine versus tacrolimus-based immunosuppression.
    Aoun B, Decramer S, Vitkevic R, Wannous H, Bandin F, Azema C, Callard P, Brocheriou I, Ulinski T.
    Pediatr Nephrol; 2013 Mar; 28(3):493-8. PubMed ID: 23111894
    [Abstract] [Full Text] [Related]

  • 9. Acute rejection features in dual kidney transplant recipients from elderly donors: comparison of calcineurin inhibitor-based and calcineurin inhibitor-free immunosuppressive protocols.
    Aiello FB, Furian L, Marino S, Marchini F, Cardillo M, De Fazio N, Rigotti P, Valente M.
    Int J Immunopathol Pharmacol; 2009 Mar; 22(4):1001-7. PubMed ID: 20074463
    [Abstract] [Full Text] [Related]

  • 10. Correlations with six-month protocol biopsy findings in pediatric transplant recipients on low- and regular-dose CNI regimens.
    Kanzelmeyer NK, Ahlenstiel T, Kreuzer M, Becker JU, Pape L.
    Clin Transplant; 2013 Mar; 27(2):319-23. PubMed ID: 23414365
    [Abstract] [Full Text] [Related]

  • 11. Benefits and risks of protocol biopsies in pediatric renal transplantation.
    Gordillo R, Munshi R, Monroe EJ, Shivaram GM, Smith JM.
    Pediatr Nephrol; 2019 Apr; 34(4):593-598. PubMed ID: 29725772
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK, Huh KH, Ha J, Kim YH, Kim YL, Kim YS.
    Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
    [Abstract] [Full Text] [Related]

  • 13. Treatment of subclinical injuries detected by protocol biopsy improves the long-term kidney allograft function: a single center prospective randomized clinical trial.
    Szederkényi E, Iványi B, Morvay Z, Szenohradszki P, Borda B, Marofka F, Kemény E, Lázár G.
    Transplant Proc; 2011 May; 43(4):1239-43. PubMed ID: 21620099
    [Abstract] [Full Text] [Related]

  • 14. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
    Nankivell BJ, PʼNg CH, OʼConnell PJ, Chapman JR.
    Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529
    [Abstract] [Full Text] [Related]

  • 15. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 16. ARFI-based tissue elasticity quantification and kidney graft dysfunction: first clinical experiences.
    Stock KF, Klein BS, Cong MT, Regenbogen C, Kemmner S, Büttner M, Wagenpfeil S, Matevossian E, Renders L, Heemann U, Küchle C.
    Clin Hemorheol Microcirc; 2011 Nov; 49(1-4):527-35. PubMed ID: 22214724
    [Abstract] [Full Text] [Related]

  • 17. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
    Cotovio P, Neves M, Santos L, Macário F, Alves R, Mota A.
    Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
    [Abstract] [Full Text] [Related]

  • 18. Immunosuppression and Graft Rejection in Living-related HLA-identical Renal Transplantation: The RADOVFULL Study.
    Ossman R, Jamme M, Moulin B, Legendre C, Morelon E, Frimat L, Hourmant M, Durrbach A, Malvezzi P, Rostaing L, Luc Taupin J, Mesnard L, Rondeau E, RADOVFULL Study Group.
    Transplantation; 2020 Jun; 104(6):1256-1262. PubMed ID: 31465001
    [Abstract] [Full Text] [Related]

  • 19. Limitations of current liver transplant immunosuppressive regimens: renal considerations.
    Zhang W, Fung J.
    Hepatobiliary Pancreat Dis Int; 2017 Feb; 16(1):27-32. PubMed ID: 28119255
    [Abstract] [Full Text] [Related]

  • 20. Calcineurin Inhibitor-Sparing Strategies in Renal Transplantation: Where Are We? A Comprehensive Review of the Current Evidence.
    Camilleri B, Bridson JM, Halawa A.
    Exp Clin Transplant; 2016 Oct; 14(5):471-483. PubMed ID: 27213490
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.